IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 59.9

Change

+0.75 (+1.27)%

Market Cap

N/A

Volume

0.35M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.82 (+1.30%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.84 (+1.27%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+1.50 (+1.42%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+0.21 (+0.23%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.63 (-2.79%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.52 (-1.66%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+2.03 (+2.18%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.03 (+0.11%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.49 (+0.81%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.58 (-2.56%)

USD 8.55M

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

-0.28 (-2.42%)

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

-0.28 (-2.42%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.80% 71% C- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.80% 71% C- 87% B+
Trailing 12 Months  
Capital Gain 1.65% 48% F 47% F
Dividend Return 1.23% 81% B- 19% F
Total Return 2.88% 48% F 37% F
Trailing 5 Years  
Capital Gain 36.13% 100% F 69% C-
Dividend Return 7.19% 74% C 20% F
Total Return 43.32% 95% A 65% D
Average Annual (5 Year Horizon)  
Capital Gain 6.31% 71% C- 55% F
Dividend Return 7.32% 76% C+ 51% F
Total Return 1.01% 79% B- 25% F
Risk Return Profile  
Volatility (Standard Deviation) 18.51% 57% F 59% D-
Risk Adjusted Return 39.54% 71% C- 54% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike